- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Journal: OCT ANGIOGRAPHY, VISUAL FIELD AND RNFL WITH VARIOUS MEDICATIONS IN HYPERTENSIVE GLAUCOMAS. (Pubmed Central) - Jan 28, 2022
The sample, consisting of 36 HTG patients (72 eyes), was divided into three subgroups: In the first group, patients were treated with combination therapy (latanoprost + timolol, latanoprost + dorzolamide + timolol, dorzolamide + timolol)...In the second group, patients were treated with beta-blockers (carteolol, betaxolol, timolol)...In the third group, patients were treated with prostaglandins (latanoprost, bimatoprost)...The measured values of the third group were taken as baseline. In the statistical analysis, we have found differences in visual field in the combination treatment group (p = 0.0006) and differences were recorded for RNFL in the beta-blocker group (p = 0.04).
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Journal: Prostaglandin analog effects on cerebrospinal fluid reabsorption via nasal mucosa. (Pubmed Central) - Jan 12, 2022
The greatest effect, partially dose-dependent, was observed using latanoprost. Further studies are needed to determine the efficacy of these agents in reducing ICP in short and long-term applications.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Journal: Prostaglandin F2 and EP2 Agonists Exert Different Effects on 3D 3T3-L1 Spheroids during Their Culture Phase. (Pubmed Central) - Dec 27, 2021
To elucidate the effects of switching a PGF2α agonist, bimatoprost acid (BIM-A), to an EP2 agonist (Omidenepag-OMD; butaprost-Buta) or reversing the switching on adipose tissue, two-dimensional (2D) and three-dimensional (3D) cultures of 3T3-L1 cells were analyzed by lipid staining and according to the mRNA expression of adipogenesis-related genes (Pparγ, Ap2, and Leptin), components of the extracellular matrix (ECM; collagen1 (Col1), Col4, Col6, and fibronectin (Fn)), and the sizes and stiffness of the 3D spheroids...In contrast, reversing the switching resulted in (1) an enhancement in lipid staining (2D) and a significant upregulation of adipogenesis-related genes (2D, 3D Buta to BIM-A), (2) larger and slightly stiffer 3D spheroids, and (3) upregulation of Col1 and Fn (2D). These collective findings indicate that the switching orders of BIM-A and EP2 agonists have a significant effect on lipid metabolism, ECM expression, and the physical stiffness of 3T3-L1 cells.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Journal: Sustained bimatoprost release using gold nanoparticles laden contact lenses. (Pubmed Central) - Nov 4, 2021
Further, they showed higher drug retention in the rabbit tear fluid compared to the SM-L lens. In conclusion, the presence of GNPs in contact lenses increased drug uptake from the soaking solution, and improved the in vitro and in vivo release kinetics without affecting the critical properties of the contact lenses for therapeutic application.
- |||||||||| AGN-193408 / AbbVie
Phase classification: AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Oct 26, 2021
P1/2, N=84, Recruiting,
In conclusion, the presence of GNPs in contact lenses increased drug uptake from the soaking solution, and improved the in vitro and in vivo release kinetics without affecting the critical properties of the contact lenses for therapeutic application. Phase classification: P2 --> P1/2
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, NN1213 / Novo Nordisk
Enrollment closed: STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - Oct 15, 2021
P3, N=500, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion date, Trial primary completion date: Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment (clinicaltrials.gov) - Oct 14, 2021
P1, N=25, Not yet recruiting,
Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Dec 2021 --> May 2022
- |||||||||| Taptiqom (tafluprost/timolol) / Santen, AGC Biologics
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Real-world evidence, Real-world: Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting (clinicaltrials.gov) - Oct 7, 2021
P=N/A, N=1, Recruiting,
Trial primary completion date: Apr 2024 --> Apr 2025 Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Aug 2022 | Initiation date: Apr 2021 --> Sep 2021 | Trial primary completion date: Dec 2021 --> Aug 2022
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion date, Trial primary completion date: Bimatoprost as a Treatment for Graves' Orbitopathy (clinicaltrials.gov) - Oct 7, 2021
P1, N=3, Recruiting,
Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Aug 2022 | Initiation date: Apr 2021 --> Sep 2021 | Trial primary completion date: Dec 2021 --> Aug 2022 Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: May 2021 --> May 2022
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Observational data, Retrospective data, Journal: Proposal of a simple grading system integrating cosmetic and tonometric aspects of prostaglandin-associated periorbitopathy. (Pubmed Central) - Sep 10, 2021
The PAP graded using SU-PAP reflects the degree of overestimation of the IOPGAT and different severities of PAP among the different prostaglandins. SU-PAP, the grade system constructed based on the underlining mechanisms of PAP, is a simple grading system for PAP that is feasible for use in a real-world clinical situation.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Review, Journal: Prostanoid receptor agonists for glaucoma treatment. (Pubmed Central) - Aug 27, 2021
Including these commercially available FP and EP2 receptor agonists, prostanoid receptors have a large potential to control intraocular pressure. In this review I will trace the history and development of FP and EP2 receptor agonists from their original function, and explain their potential as first-line drugs including elucidation of their efficacy and safety.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Journal: Effect of the Antiglaucoma Agent JV-GL1 and Related Compounds in the Canine Eye. (Pubmed Central) - Aug 12, 2021
JV-GL1, as a 0.01% eye drop, produced significantly greater reductions in IOP than the original clinical dose of bimatoprost (0.03%)...A similar degree of ocular surface redness was apparent for both compounds, given as eye drops, but no other effects occurred. Results with PGN 9862 and its isopropyl ester confirmed that PGN 9862-isopropyl ester is not bioavailable in the eye and not susceptible to enzymatic hydrolysis in ocular tissues, a first for C1 ester prodrugs in the eye.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Preclinical, Journal: The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice. (Pubmed Central) - Aug 4, 2021
Purpose: The present study investigated the effects of the antiglaucoma agent and selective E2 receptor agonist omidenepag isopropyl (OMDI) on eyelash growth in comparison with a prostaglandin analog (prostamide receptor agonist) in mice. Unlike existing prostaglandin analogs, our findings indicate that OMDI has no effect on eyelash growth in mice, suggesting that it may be a promising antiglaucoma agent with a reduced number of adverse effects.
- |||||||||| bimatoprost ophthalmic (T4032) / Thea Laboratories
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Efficacy and Safety Assessment of T4032 Versus Lumigan (clinicaltrials.gov) - Jul 28, 2021
P3, N=485, Completed,
Literature review has demonstrated case reports supporting periocular hyperpigmentation; however, there has been no description of progression to periocular lentigo maligna and melanoma in a patient using bimatoprost. Recruiting --> Completed | N=360 --> 485 | Trial completion date: May 2020 --> Feb 2021 | Trial primary completion date: Apr 2020 --> Feb 2021
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Journal: Cystoid macula edema related to cataract surgery and topical prostaglandin analogs: mechanism, diagnosis, and management. (Pubmed Central) - Jul 8, 2021
It has been proposed that eyes with elevated intraocular pressure after cataract surgery, including those treated with prostaglandin analog eye drops, may be at higher risk for developing CME. We summarize the current knowledge of the molecular mechanisms underlying CME, the potential role of ocular surgery and topical glaucoma medication in increasing the risk of CME, the newly developed imaging methods for diagnosing CME, and the clinical management of CME.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Retrospective data, Review, Journal: Treatments for alopecia areata: a systematic review and network meta-analysis. (Pubmed Central) - Jul 2, 2021
Even with the network meta-analysis, we could not identify the best treatment because of independent loops and wide confidence intervals. Treatment options above may be reasonable strategies, but further comparison is required.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Journal: Omidenepag, a Selective, Prostanoid EP2 Agonist, Does Not Suppress Adipogenesis in 3D Organoids of Human Orbital Fibroblasts. (Pubmed Central) - Jun 30, 2021
During adipogenesis of 3D HOFs organoids, changes in size, lipids staining, mRNA expression of adipogenesis related genes, PPARγ, AP2, and ADIPOQ, and extracellular matrix, collagen 1 (COL 1), COL 4, COL 6, and fibronectin (FN), and stiffness by a micro-squeezer were examined in the presence and absence of either 100 nM bimatoprost acid (BIM-A) or 10, 100, or 10,000 nM OMD...The present study indicates that the FP2 agonist, OMD, had different effects on 3D HOFs organoids, as compared to BIM-A. The current study suggests that OMD may not induce deepening of upper eyelid sulcus (DUES).
- |||||||||| Eucrisa (crisaborole) / Pfizer, Lumigan (bimatoprost) / Senju, AbbVie
Review, Journal: Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review. (Pubmed Central) - May 25, 2021
Oral (apremilast) and topical (crisaborole) PDEIs and topical prostaglandin analogues, including latanoprost and bimatoprost, were found safe and effective in different skin diseases. In terms of efficiency and safety, these medicines compete with other medications of similar use even with higher efficacy and fewer side effects that necessitate further studies.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Preclinical, Journal: Efficacy, Drug Sensitivity, and Safety of a Chronic Ocular Hypertension Rat Model Established Using a Single Intracameral Injection of Hydrogel into the Anterior Chamber. (Pubmed Central) - May 21, 2021
Response to 5 common drugs (brimonidine, timolol, benzamide, pilocarpine, and bimatoprost) were each tested on 6 rats and assessed using difference in IOP...CECs at 2, 4, and 8 weeks showed no significant differences from control groups in results of histological analysis, TUNEL, and CCK-8 assays. CONCLUSIONS A single injection of hydrogel into the anterior chamber is effective for modeling COH, can respond to most commonly used hypotensive drugs, and is non-toxic to the eyes.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie, Durysta (bimatoprost implant) / AbbVie
Enrollment closed: A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - May 20, 2021
P3, N=35, Active, not recruiting,
CONCLUSIONS A single injection of hydrogel into the anterior chamber is effective for modeling COH, can respond to most commonly used hypotensive drugs, and is non-toxic to the eyes. Recruiting --> Active, not recruiting
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
[VIRTUAL] The effect of intraocular pressure-lowering drugs on non-pigmented ciliary epithelium-derived exosomes interactions and their impact on trabecular meshwork internalization () - May 13, 2021 - Abstract #ARVO2021ARVO_2055;
To evaluate the ionic strength (IS) effects on exosomes size and ZP, different PBS buffer strengths, eye drops solutions used for POAG treatment; Alphagan-P®, V-OPTIC®, AZOPT®, Lumigan®, and Travatan®, their active ingredients; Timolol maleate, Brinzolamide or their preservative benzalkonium chloride were analyzed. Our findings suggest that exosomes size, surface membrane charge, and IS of the surrounding, have an impact on exosomes:exosomes interactions which affect the uptake of NPCE exosomes by TM cells.
- |||||||||| Lumigan (bimatoprost) / Senju, AbbVie
Trial completion date, Trial initiation date, Trial primary completion date: Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment (clinicaltrials.gov) - May 2, 2021
P1, N=25, Not yet recruiting,
Further studies are currently ongoing to better understand how these treatments are affecting the trabecular meshwork. Trial completion date: Aug 2021 --> Dec 2021 | Initiation date: Feb 2021 --> Aug 2021 | Trial primary completion date: Aug 2021 --> Dec 2021
|
